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Abstract
Introduction: Women with previous gestational diabetes mellitus (GDM) have increased risk of developing glucose abnormality, but current di-
agnostic criteria are evidence-based for adverse pregnancy outcome. The aims of our study were: (i) to ascertain a frequency of early conversion 
of GDM into permanent glucose abnormality, (ii) to determine predictive potential of current GDM diagnostic criteria for prediction of postpartum 
glucose abnormality and (iii) to find optimal cut-off values of oral glucose tolerance test (oGTT) to stratify GDM population according to postpartum 
risk.
Materials and methods: Electronic medical records of an ethnically homogenous cohort of women diagnosed and treated for GDM in a single 
medical centre during the period 2005–2011 who completed postpartum oGTT up to 1 year after the index delivery were retrospectively analysed 
(N = 305).
Results: Postpartum glucose abnormality was detected in 16.7% subjects. Mid-trimester oGTT values, respective area under the curve and HbA1c 
were significantly associated with early postpartum glucose abnormality (P < 0.05, Mann-Whitney) and exhibited significant predictive potential 
for postpartum glucose abnormality risk assessment. Optimal cut-off values for discrimination of at-risk sub-population were identified using ROC 
analysis and their comparison with WHO and IADPSG criteria exhibited superiority of IADPSG for risk-stratification of GDM population.
Conclusion: Risk-based stratification at the time of GDM diagnosis could improve efficiency of the post-gestational screening for diabetes. IADPSG 
criteria seem to optimally capture both perinatal and maternal metabolic risks and are therefore medically and economically justified.
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Gestational diabetes mellitus (GDM), a common 
complication of pregnancy, is defined as any de-
gree of glucose intolerance with the onset or the 
first recognition during the pregnancy (most often 
during the second trimester of gestation) which 
then typically normalizes after the delivery (or pu-
erperium) (1). Pregnancy is a relatively short period 
marked by dramatic changes of hormone profile 
and body composition with profound effects on 
metabolism. While the initial phase is usually char-
acterized by increased insulin sensitivity, later 
marked insulin resistance develops (2), which, in a 
subset of women with latent defect of insulin se-
cretion, manifests as a GDM. 
Although the reported prevalence of GDM varies 
considerably between countries mainly due to dif-
ferent diagnostic criteria used, the incidence of 
GDM is reported to rise worldwide (3). Hypergly-
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caemia and Adverse Pregnancy Outcomes study 
(HAPO) (4) prompted an important shift in the 
GDM paradigm since it provided grounds for the 
evidence-based modification of GDM diagnostic 
criteria showing that perinatal morbidity (high 
birth weight leading to complications during de-
livery such as shoulder dystocia, birth injury, hy-
perbilirubinemia, neonatal hypoglycaemia, foetal 
hyperinsulinemia reflected by increased cord-
blood serum C-peptide levels) is proportionately 
related to maternal glycaemia. Recently Interna-
tional Association of Diabetes and Pregnancy 
Study Groups (IADPSG) proposed new criteria for 
GDM reflecting HAPO results (5). Applying IADPSG 
diagnostic criteria on HAPO study population the 
GDM incidence would reach 17.8% (6).
GDM elicits a complex medical situation affecting 
yet two people - mother and child - in the short-
term as well as in the long-term perspectives. 
Timely diagnosis of GDM (esp. when applying evi-
dence-based criteria) should improve short-term 
pregnancy and perinatal outcomes and newly 
proposed IADPSG diagnostic criteria are domi-
nantly pregnancy risk-based. However, the extent 
of risk reduction is often regarded as minor (oral 
glucose tolerance test (oGTT) cut-off values calcu-
lated for “only” 75% reduction of adverse preg-
nancy outcomes) and disproportionate to the ex-
tra health care cost related to increased GDM prev-
alence when using more stringent criteria. Since 
recommendations issued by IADPSG will have ma-
jor implications for the health care systems this 
stimulates an intense debate among relevant au-
thorities in many countries (7) including Czech Re-
public. While Czech Diabetes Society adopted the 
IADPSG diagnostic criteria in April 2014, Czech Gy-
naecology and Obstetrics Society remains reluc-
tant to their universal adoption and no official 
statement has yet been issued (8). One of the pos-
sible reasons for this hesitation in obstetric com-
munity (worldwide though) might be a paucity of 
data available on long-term consequences of 
GDM.
GDM is an established lifelong risk factor for the 
development of diabetes in women with GDM his-
tory. The estimation of the prevalence of perma-
nent postpartum dysglycaemia (prediabetes or di-
abetes) was the subject of several studies during 
the past 20 years, part of them were included in a 
systematic review (9) or in a meta-analysis com-
prising about 675,000 of women with GDM diag-
nosis (10). In spite of limitations of this approach 
(such as variable follow-up, study design, actual 
GDM diagnostic criteria, definition of end-points 
and ethnicity) women with previous GDM had at 
least 7-fold increase of risk of developing type 2 
diabetes mellitus (T2DM) in the future compared 
with those with normoglycaemia during pregnan-
cy (10). Furthermore, cumulative incidence of 
T2DM was shown to increase steadily during the 
first 5 years after the delivery, reaching a plateau in 
10 years postpartum (9). 
We therefore hypothesize that documented early 
reoccurrence or even postpartum persistence of 
glucose abnormality gives a very good chance for 
an early postpartum screening to detect a largest 
proportion of at-risk women. Furthermore, being 
able to stratify GDM population according to the 
risk of subsequent glucose metabolism abnormal-
ity as soon as possible (ideally already during the 
pregnancy), the generally unsatisfactorily low 
compliance in postpartum diabetes screening 
(11,12) could improve thanks to more persuasive 
arguments and possibly increased motivation of 
at-risk subgroup. Therefore, given that women 
with previous GDM have significantly increased 
risk of postpartum glucose abnormality and 
screening for GDM is very well developed and 
widespread, however, none of the current diag-
nostic criteria are evidence-based for prediction of 
postpartum maternal risks, the aims of our study 
were: (i) to ascertain a frequency of early postpar-
tum (up to 12 months post-delivery) conversion of 
GDM into permanent diabetes or prediabetes, (ii) 
to determine a predictive potential of national 
modification of the World Health Organisation 
(WHO) diagnostic criteria used at the time of sub-
ject’s enrolment and currently recommended 
IADPSG diagnostic criteria for prediction of post-
partum glucose abnormality and (iii) to find opti-
mal cut-offs of oGTT values capturing mother’s 
metabolic risks to stratify GDM population accord-
ing to postpartum risk of glucose abnormality. 
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Materials and methods 
Study design and subjects 
Study was designed as a retrospective, electronic 
health records (EHR) based study of ethnically ho-
mogenous cohort of GDM subjects (Caucasian ori-
gin, geographically derived from South Moravia 
region of Czech Republic) who underwent their 
mid-gestational GDM screening by oGTT and were 
subsequently diagnosed and followed for GDM in 
outpatient clinics (Diabetes Centre of the Universi-
ty Hospital Brno, Czech Republic) from January 
2005 till December 2011. University Hospital Brno 
is a public non-profit tertiary medical centre, one 
of the largest in Czech Republic, serving the area 
of Brno city and South Moravia district with ap-
proximately 1.2 million inhabitants. EHRs organiz-
es digitalised patient-level data shared among 
multiple facilities, outpatient and inpatient clinics 
of three units of the University Hospital Brno (i.e. 
Hospital Brno-Bohunice, Children Hospital Brno 
and Centre for Reproductive Medicine) that are ac-
cessible real-time. Data are available either in codi-
fied form (demographic and anthropometric data, 
codes of diagnoses and procedures, list of chrono-
logical visits to health care professionals, images 
and laboratory test results, insurance and billing 
data etc.) or as a clinical narrative notes (family and 
patient’s medical history, medications, treatment 
plans, records of hospitalization etc.). Data were 
retrieved from EHRs based on the following inclu-
sion criteria: (i) GDM diagnosis classified by Inter-
national Classification of Diseases (ICD)-10 code 
O24.4 or O24.9, (ii) GDM diagnosed by 3-point 75 g 
of glucose 2-h oGTT between 24th and 28th week 
of pregnancy at the University Hospital Brno, (ii) 
completed postpartum oGTT 6 weeks up to 1 year 
after the indexed delivery. Exclusion criteria were: 
(i) pre-gestational type 1 diabetes mellitus (T1DM), 
T2DM or abnormal glucose tolerance (i.e. O24.0–
O24.3 or R73) and (ii) GDM diagnosed by oGTT 
outside the University Hospital Brno. Following 
data mining, extensive data checks and quality 
control were performed incl. cross-checking the 
GDM ICD-10 code and the results of the mid-ges-
tational oGTT to finalise the study sample. A total 
of N = 305 GDM subjects were included in the 
study. The data mining and analysis were fully an-
onymised. Study was approved by the Ethical 
committee of the University Hospital Brno and 
Ethical committee of Faculty of Medicine, Masaryk 
University and its conduct was in compliance with 
the Helsinki Declaration.
Methods
According to the current practice in Czech Repub-
lic screening for GDM is offered to all pregnant 
women (with exception of pre-existing diabetics) 
in second trimester. In case of the presence of at 
least two risk factors (positive family history, previ-
ous delivery of new-born with weight above 4000 
g, obesity, diabetes mellitus in previous pregnan-
cy, glycosuria, previous stillborn delivery, hyper-
tension or preeclampsia in previous pregnancy, re-
peated abortions, age above 30 years) it should be 
performed during the first trimester. Diagnosis of 
GDM in the cohered diagnosed and followed in 
2005–2011 period was based on the consensus cri-
teria of Czech Diabetes Society and Czech Society 
for Clinical Biochemistry (13) derived from WHO 
criteria for subjects with impaired fasting glucose 
(IFG) / impaired glucose tolerance (IGT) (14) using a 
3-point oGTT with 75 g glucose with threshold val-
ues (any value above cut-off diagnosing GDM): 
FPG ≥ 5.6 mmol/L, 1-hr after 75 g load glucose ≥ 
8.8 mmol/L and/or 2-hr after 75 g load ≥ 7.8mmol/L 
(sample 60 minutes after challenge optional but 
recommended). Glycaemia was measured by 
hexokinase-based enzymatic method using Co-
bas 8000 analyser and commercial reagents 
(Roche) in venous plasma. HbA1c (cut off 39 
mmol/mol) was measured in all subjects by ion-
exchange high-performance liquid chromatogra-
phy (HPLC) using D-10 analyser and commercial 
reagents (Bio-Rad) in whole blood. Additionally, 
area under the curve (AUC, mmol/L/hour) was 
calculated from a 3-point oGTT using the trape-
zoid rule (15). Cut-offs of newly recommended 
IADPSG criteria are as follows: FPG ≥ 5.1mmol/L, 
1-hr post-load glucose: ≥ 10.0 mmol/L, 2-hr post-
load glucose: ≥ 8.5 mmol/L.
Postpartum diagnosis of diabetes/prediabetes was 
based on the WHO criteria: FPG ≥ 7mmol/L alone 
or 2-hr after 75 g load glucose ≥ 11.1mmol/L for 
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DM, FPG 5.6–6.9mmol/L or 2-hr after 75 g load 
glucose 7.8-11.0 mmol/L for prediabetes. In the 
case of postpartum diagnosis of manifest diabetes 
urinary ketone bodies, C-peptide and antibodies 
(anti-glutamic acid decarboxylase (anti-GAD), anti-
tyrosine phosphatase (antiIA-2), insulin auto-anti-
bodies (IAA)) were measured to identify an even-
tual T1DM. 
Statistical analysis
Data are expressed as medians and interquartile 
ranges (IQR) or proportions for between group 
comparisons. Differences between groups were 
compared using non-parametric Mann-Whitney 
or Pearson chi-square tests for continuous or cate-
gorical variables, respectively, using Statistica for 
Windows (Statsoft Inc., Tulsa, OK, USA) software. P 
≤ 0.05 was considered statistically significant un-
less correction for multiple comparisons were ap-
plied (Pcorr). Univariate and multivariate logistic 
models were constructed to determine an eventu-
al statistically significant effect of any relevant vari-
able and Receiver Operating Characteristic (ROC) 
analysis was applied to test the final models. Areas 
under the ROC curve (AUCROC) were compared by 
Delong paired test (16). Optimal cut-off of selected 
glycaemic indices for prediction of postpartum 
GDM conversion into permanent glucose abnor-
mality within 12 month were selected by the high-
est Youden indices (17), i.e. single statistic captur-
ing diagnostic test performance (J = sensitivity + 
specificity – 1) with value ranging from 0 to 1 (a 
zero value for the test giving the same proportion 
of positive results for groups with and without the 
disease and a value of 1 for no false positives or 
negatives). 
Results 
Incidence of postpartum glucose abnormality
Incidence of any disorder of glucose metabolism 
(i.e. diabetes or prediabetes) up to 1 year postpar-
tum was 16.7% (N = 51/305). Of those, 62.7% had 
prediabetes (N = 32, 14 had IFG and 18 had IGT), 
37.3% (N = 19) had manifest diabetes. Based on 
the examination of urinary ketone bodies, C-pep-
tide and antibodies (anti-GAD, antiIA-2, IAA) 31.4% 
(N = 16) had T2DM and 5.9% (N = 3) had T1DM.  
Relationship between mid-trimester 
parameters and postpartum glucose 
intolerance 
Characteristics of subjects at the time of GDM di-
agnosis with respect to their postpartum GDM 
normalization or persistence are shown in Table 1. 
Glycaemia in all three time-points of mid-trimester 
oGTT, AUCoGTT and mid-trimester HbA1c were sig-
nificantly higher in the group of GDM women with 
the postpartum disorder compared to those with 
normal glucose tolerance (NGT) postpartum. Us-
ing categorial approach, i.e. comparing number of 
oGTT values under/above threshold, highly signifi-
cant difference was found (P < 0.001) with the ob-
vious trend towards the more frequent postpar-
tum abnormality the higher the number of mid-
trimester oGTT values above threshold. About 8% 
(16 from 203) of GDM patients with one oGTT val-
ue above threshold were diagnosed with glucose 
abnormality 1 year postpartum, 27% (22 from 82) 
with two oGTT values (OR for post-partum glucose 
intolerance 4.3-times higher than for those with 
one value above the threshold [95% CI = 2.1-8.7], P 
< 0.001) and 65% (13 from 20) with all three oGTT 
values (OR 21.7-times higher than for patients who 
have only one value oGTT above the threshold 
[95% CI = 7.6-62.1], P < 0.001 and 5.1-times higher 
than for patients who had two oGTT values above 
the threshold [95% CI = 1.8-4.3], P = 0.002).
Predictive potential of routine mid-trimester 
parameters for postpartum glucose 
intolerance
Series of uni- and multivariate logistic regression 
models were constructed for both continuous (i.e. 
oGTT values, AUCoGTT and HbA1c) and categorial 
data (respective below/above-threshold values). 
Upon exclusion of mutually correlated variables fi-
nal multivariate models identified (A) all three 
oGTT values above threshold, i.e. FPG (OR = 6.32, 
[95% CI = 2.96-13.78], P < 0.001), 1-hr post 75 g load 
glucose (OR = 4.33, [95% CI = 1.84-12.02], P = 0.002) 
and 2-hr post 75 g load glucose (OR = 3.88, [95% CI 
= 1.95-7.91], P < 0.001) as significant predictors of 
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postpartum glucose abnormality applying catego-
rial approach. Analogical multivariate logistic 
model constructed for (B) continuous variables 
identified HbA1c (OR = 2.31, [95% CI = 1.01-5.39], P 
= 0.048), FPG (OR = 2.00, [95% CI = 1.18-3.42], P = 
0.011) and 1-hr post 75 g load glucose (OR = 1.42, 
[95% CI = 1.13-1.81], P = 0.004) as significant predic-
tors of postpartum glucose abnormality. 
Finally, using ROC analysis combined with Youden 
statistics we attempted to find optimal cut-off val-
ues of parameters evaluated at mid-trimester best 
reflecting postpartum risk in our study population 
(see Table 2) and to determine to which extent 
they differ from the newly proposed IADPSG crite-
ria. Following cut-off values for the prediction of 
postpartum glucose abnormality in our study 
population were identified (current WHO/recom-
mended IADPSG diagnostic thresholds for GDM 
diagnosis according to Czech Diabetes Society are 
shown in brackets): FPG ≥ 5.1mmol/L, (≥ 5.6mmol/L 
/ ≥ 5.1mmol/L), 1-hr post 75 g load glucose ≥ 10.7 
mmol/L (≥ 8.8 mmol/L / ≥ 10 mmol/L) and 2-hr 
post 75 g load glucose  7.8 mmol/L, (≥ 7.7 mmol/L / 
≥ 8.5 mmol/L).
Parameters
GDM subjects with postpartum 
NGT
(N = 254)






Age (years) 32 (29–35) 32 (30–37) 0.155
Parity 2 (1–2) 2 (1–3) 0.161
Week of gestation∗ 28 (26–28) 28 (25–28) 0.595
Pre-gestational BMI 27.9 (24.8–31.6) 28.4 (24.3–32.2) 0.997
Total cholesterol (mmol/L) 5.3 (4.7–6.3) 4.8 (4.2–5.8) 0.139
Family history of DM (%) 75 68 0.328
Pregnancy after IVF (%) 4 7 0.224
HbA1C (mmol/mol) 33 (31–36) 36 (33–38) < 0.001
Mid-gestation oGTT (24-28th week of gestation)
FPG (mmol/L) 4.7 (4.3–5.1) 5.2 (4.7–5.9) < 0.001
1-h post 75 g load 9.4 (8.8.–10.1) 10.6 (9.2–11.7) < 0.001
2-h post 75 g load 7.5 (6.3–8.2) 8.0 (7.0–9.3) 0.003
AUCoGTT (mmol/L/hour) 15.2 (14.4–16.2) 17.1 (15.3–18.5) < 0.001
Postpartum oGTT (6 weeks -12 months after delivery)
FPG (mmol/L) 4.7 (4.5–5.0) 5.7 (4.7–6.1) < 0.001
1-h post 75 g load 7.5 (6.4–8.5) 10.5 (8.8–11.6) < 0.001
2-h post 75 g load 5.4 (4.5–6.4) 8.0 (6.3–11.0) < 0.001
AUCoGTT (mmol/L/hour) 10.2 (9.3–11.1) 12.8 (12.2–16.4) < 0.001
Data expressed as a median (IQR) or proportions. Differences evaluated by nonparametric Mann-Whitney or chi-square 
test, respectively. Considering multiple comparisons involved Bonferoni correction (Pcorr ≤ 0.05 / number of tests) was 
applied and only Pcorr ≤ 0.004 should be considered significant. 
∗Week of gestation at the time of GDM diagnosis.
AUCoGTT – area under oGTT curve; BMI – body mass index; DM – diabetes mellitus; FPG – fasting plasma glucose; HbA1c – 
glycated haemoglobin; IVF – in vitro fertilisation; NGT – normal glucose tolerance; oGTT – oral glucose tolerance test.
Table 1. Characteristics of study subjects at the time of GDM diagnosis (24-28th gestational week) and postpartum. 
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Discussion 
In this report, using a cohort of 305 metabolically 
well characterized GDM subjects we ascertained 
incidence of post-GDM glucose abnormality 16.7% 
the first year postpartum, during which time 10.5% 
of women with GDM history manifested prediabe-
tes, 5.2% T2DM and 1% T1DM. Furthermore, we 
demonstrated that routine glycaemic parameters 
(FPG, 1-h and 2-h post 75 g load glucose) exam-
ined in all pregnant women as a part of their 
standard antenatal care can reliably predict early 
postpartum glucose intolerance and thus improve 
health outcomes and perspectives in this group of 
young women at high risk for diabetes (10) and 
cardiovascular diseases (18). Finally, optimal cut-off 
values for maternal risk of postpartum diabetes as-
certained in our sample are in general very close 
to the IADPSG criteria that are evidence-based for 
the perinatal outcomes.
As mentioned earlier, early postpartum screening 
has a great chance to detect glucose abnormality 
in large proportion of women who can then be ef-
ficiently intervened. For this reason we studied 
population of GDM cases who have been re-test-
ed within the first 12 months postpartum since – 
according to our view – positive attitude towards 
lifestyle changes lasting for some time after preg-
nancy might still span the early postpartum peri-
od and repeated oGTT is thus attended by a realis-
tic maximum of cases. In spite of the currently 
practiced recommendations – to repeat testing for 
diabetes or prediabetes roughly 3-6 months after 
delivery and then every 3 years (19), considerable 
proportion of women with GDM history fail to turn 
up (11,12). This is quite unfortunate considering di-
abetes development is largely preventable by life-
style and pharmacologic interventions (20). 
This unsatisfactorily low compliance in postpar-
tum screening can either be changed by various 
strategies to increase motivation of GDM patients 
to seek the postpartum test or by timely antepar-
tum stratification of GDM cases according to their 
post-gestational metabolic risk. The latter strategy 
– selective postpartum follow-up of high risk sub-
group is according to our view more effective and 
prompted us to undertake the current study. 
Although it is physiologically highly plausible that 
the degree of impairment of glucose homeostasis 
in pregnancy is continually reflected in the post-
partum glucose (in)tolerance, studies relating an-
tepartum glycaemic indices to postpartum status 
with the attempt to quantitatively estimate the 
risk and to predict postpartum diabetes are still 
limited. Previous studies have shown post-load 
glucose levels (1-hr, 2-hr or 3-hr of antepartum 
oGTT) (21) or FPG (22) or all of these (23) associated 
with postpartum glucose abnormality. Retnakaran 
et al. reported prevalence of postpartum glucose 
intolerance progressively increased across the 
continuous spectrum of women with metabolical-
ly distinct glucose tolerance (including NGT) as-
sessed by the combination of glucose challenge 
test and oGTT at mid-pregnancy (24). Ekelund et 
Parameters Cut-off according to Youden index AUC 95 % CI P
HbA1c (mmol/mol) ≥ 36 0.675 0.619–0.728 < 0.001
FPG during oGTT ≥ 5.1 0.692 0.637–0.743 < 0.001
oGTT 1-h post 75 g load glucose ≥ 10.7 0.694 0.639–0.745 < 0.001
oGTT 2-h post 75 g load glucose ≥ 7.8 0.630 0.573–0.684 0.006
AUC – area under the curve; CI – confidence interval; FPG – fasting plasma glucose; HbA1c – glycated haemoglobin; 
oGTT – oral glucose tolerance test.
Table 2 . ROC analysis combined with Youden statistics identifying optimal cut-off values of parameters evaluated at mid-trimester 
best reflecting postpartum risk in our study population.
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al. showed that FPG and HbA1c were significant 
predictors of postpartum diabetes (25). Finally, an-
tepartum disposition index was shown to be pre-
dictive for postpartum glucose intolerance (26). 
However, majority of these studies employed ei-
ther (i) medical practice distinct from the one cur-
rently provided in our country (and most of the 
Europe) such as two-step screening algorithm, 
higher glucose load in diagnostic oGTT (100 g), 
more frequent sampling (including 30 min and/or 
3-hr), later testing spanning the third trimester, (ii) 
longer postpartum follow-up or (iii) measure-
ments done solely for the research purposes not 
covered by a standard medical care such as insulin 
measurement to assess insulin sensitivity (HOMA 
insulin resistance index, insulin sensitivity index) 
and beta cell function (HOMA beta cell index, insu-
linogenic and oral disposition index). 
In the current study we found significantly higher 
mid-gestation FPG, 1-hr and 2-hr post-75g load 
glucose, AUCoGTT and HbA1c in GDM women with 
persistent postpartum glucose metabolism abnor-
mality compared to those with NGT postpartum. 
Relative risk of post-partum persistence of glucose 
intolerance gradually increased with the number 
of above threshold values whereas all three gly-
caemic indices above threshold (i.e. FPG, 1-hr and 
2-hr post 75 g load glucose) conferred independ-
ent predictive potential for postpartum glucose 
intolerance. Inclusion of HbA1c among the stand-
ard screening/diagnostic parameters for GDM 
might be profitable due to limited reproducibility 
of oGTT (27), however further studies are required 
to assess the cost-benefit relationship.  
Possibility to reliably predict postpartum diabetes 
using routine and financially covered parameters 
assessed in mid-gestation is a desirable scenario; 
however, former non-evidence-based WHO diag-
nostic criteria did not seem to reflect both relevant 
medical outcomes – i.e. short-term neonatal and 
obstetrical risks nor long-term maternal metabolic 
risk – to the same extent as shown by several stud-
ies (28,29). Although the initial diagnostic criteria 
of GDM proposed by Carpenter and Coustan (30) 
were based primarily on the risk of subsequent 
maternal diabetes, further modifications incl. 
IADPSG criteria favoured predominantly the peri-
natal risks. It becomes increasingly apparent that a 
dual set of diagnostic criteria might be necessary if 
we should capture all adverse outcomes of GDM 
including postpartum maternal glucose abnor-
mality. Due to this reason we applied ROC analysis 
to find optimal discriminating cut-offs (yielding 
the highest AUCROC) for mid-gestation FPG, 1-hr 
and 2-hr post 75 g load glucose and HbA1c. The 
actual suggested cut-offs are more stringent for 
FPG (≥ 5.1 mmol/L) than those currently practiced 
according to WHO criteria (≥ 5.6 mmol/L) and are 
in fact identical with consensus criteria derived 
from the HAPO study recommended by IADPSG 
(≥ 5.1 mmol/L). Furthermore, our analysis justifies 
the relevance of 1-h post 75 g load glucose meas-
urement since the suggested 2-h cut-off value 
equals to the current WHO GDM diagnostic value. 
Postpartum glucose abnormality risk-based 1-h 
post 75 g load cut-off (≥ 10.7 mmol/L) is less inclu-
sive than the current GDM criteria by IADPSG 
(≥ 10 mmol/L). We can therefore speculate that 
substantially elevated 1-h post 75 g load glucose 
(possibly in combination with HbA1c > 36 mmol/
mol) is the most sensitive and discriminative pa-
rameter distinguishing subset of DM cases with in-
creased risk of postpartum glucose abnormality.
We are of course aware of several limitations such 
as that our study cohort does not represent the 
entire GDM population and model constructed 
from a retrospective data of single cohort study 
with possible selection bias needs to be replicated 
and validated. Furthermore, direct comparison of 
former and new (IADPSG) WHO criteria in terms of 
sensitivity and specificity is unfortunately not pos-
sible in the same study sample since it was recruit-
ed by former national modification of WHO criteria 
and is therefore distorted by different cut-offs (esp. 
higher upper limit for FPG). Nevertheless, as a 
proof of principle this study provides incentive to 
explore the predictive potential of routine diag-
nostic criteria in larger scale studies.     
The major message of the current study is princi-
pally conveyed by the finding that prevalence of 
early postpartum glucose abnormality is not negli-
gible and reaches 16.7% during the first year post-
delivery. Furthermore, by annotation of current 
GDM diagnostic criteria it appears possible to yield 
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extra information not only on obstetrical and neo-
natal but also maternal metabolic risks. Apparent-
ly, currently practiced simple dichotomization of 
the mid-trimester oGTT into physiological and 
pathological reduces information gained from a 
standard routine well accessible test. Modification 
of the criteria with the complex view (e.g. dual set 
of cut-offs) of both obstetrical/neonatal and future 
metabolic risk could help to identify high risk pop-
ulation to be followed immediately postpartum at 
no additional cost on top of routine antenatal care. 
The documented efficiency of early diagnosis and 
lifestyle or pharmacological intervention on pre-
vention or postponing diabetes development is a 
powerful argument for further development of 
risk-based model. Subsequent long-term health 
care economic benefits represent significant add-
ed value of the proposed approach.  
In conclusion, parameters of glucose metabolism 
measured during 24-28th week of pregnancy ful-
filling criteria of GDM diagnosis exhibited highly 
statistically significant differences between wom-
en with and without persistent postpartum glu-
cose metabolism abnormality and conferred sig-
nificant predictive potential for early postpartum 
glucose abnormality. Considering generally low-
compliance of GDM women in postpartum screen-
ing, risk-based stratification of GDM population 
could improve efficiency of the screening for dia-
betes after the delivery and decrease the burden 
of its metabolic and cardiovascular consequences 
in this high-risk population. IADPSG criteria recom-
mended by Czech Diabetes Society (and in many 
other countries in Europe) seem to optimally cap-
ture both perinatal and maternal metabolic risks 
and are therefore medically and economically jus-
tified.
Acknowledgement
The authors thank the management of the Univer-
sity Hospital Brno for consent to use their elec-
tronic health record system. The authors also 
thank Tomáš Barták and Zdeněk Kratochvíl for a 
technical assistance with data mining and quality 
control. This study was supported by grant 
NT/11405 from Ministry of Health of Czech Repub-
lic. 
Potential conflict of interest
None declared.
References
 1 . American Diabetes Association Clinical Practice Re-
commendations 2001 . Diabetes Care 2001;24 Suppl 1:S1-
133 . http://dx .doi .org/10 .2337/diacare .24 .1 .1 .
 2 . Newbern D, Freemark M . Placental hormones and the con-
trol of maternal metabolism and fetal growth . Curr Opin 
Endocrinol Diabetes Obes 2011;18:409-16 . http://dx .doi .
org/10 .1097/MED .0b013e32834c800d .
 3 . Reece EA, Leguizamón G, Wiznitzer A . Gestational diabetes: 
the need for a common ground . Lancet 2009;373:1789-97 . 
http://dx .doi .org/10 .1016/S0140-6736(09)60515-8 .
 4 . Metzger BE, Lowe LP, Dyer AR, Trimble ER, Chaovarindr U, 
Coustan DR, et al . Hyperglycemia and adverse pregnancy 
outcomes . N Engl J Med 2008;358:1991-2002 . http://dx .doi .
org/10 .1056/NEJMoa0707943 .
 5 . Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catala-
no PA, Damm P, et al . International association of diabetes 
and pregnancy study groups recommendations on the di-
agnosis and classification of hyperglycemia in pregnancy . 
Diabetes Care 2010;33:676-82 . http://dx .doi .org/10 .2337/
dc10-0719 .
 6 . Weinert LS . International Association of Diabetes and 
Pregnancy Study Groups recommendations on the dia-
gnosis and classification of hyperglycemia in pregnancy: 
comment to the International Association of Diabetes and 
Pregnancy Study Groups Consensus Panel . Diabetes Care 
2010;33:e97; author reply e98 . http://dx .doi .org/10 .2337/
dc10-0544 .
 7 . Lovrencić MV, Honović L, Kralik S, Matica J, Prasek M, Pa-
pe-Medvidović E, et al . Redefinition of gestational diabe-
tes mellitus: implications for laboratory practice in Cro-
atia . Biochem Med (Zagreb) 2013;23:7-11 . http://dx .doi .
org/10 .11613/BM .2013 .002 .
 8 . Krejci H, Anderlova K . [Why do we still hesitate to accept 
the new international criteria for the diagnosis of gestatio-
nal diabetes mellitus? The current screening is non-uniform 
and does not correspond with evidence-based medicine] . 
Ceska Gynekol 2014;79:206-12 . (in Czech)
 9 . Kim C, Newton KM, Knopp RH . Gestational diabetes and 
the incidence of type 2 diabetes: a systematic review . Dia-
betes Care 2002;25:1862-68 . http://dx .doi .org/10 .2337/dia-
care .25 .10 .1862 .
Biochemia Medica 2015;25(3):460–8  http://dx .doi .org/10 .11613/BM .2015 .047 
468
Bartáková V. et al. How to predict postpartum glucose abnormality? 
10 . Bellamy L, Casas JP, Hingorani AD, Williams D . Type 2 dia-
betes mellitus after gestational diabetes: a systematic re-
view and meta-analysis . Lancet 2009;373:1773-79 . http://
dx .doi .org/10 .1016/S0140-6736(09)60731-5 .
11 . Hunt KJ, Logan SL, Conway DL, Korte JE . Postpartum scree-
ning following GDM: how well are we doing? Curr Diab Rep 
2010;10:235-41 . http://dx .doi .org/10 .1007/s11892-010-
0110-x .
12 . Keely E . An opportunity not to be missed--how do we im-
prove postpartum screening rates for women with gesta-
tional diabetes? Diabetes Metab Res Rev 2012;28:312-16 . 
http://dx .doi .org/10 .1002/dmrr .2274 .
13 . Friedecký B, Zima T, Kratochvíla J, Springer D . [Diabetes 
mellitus -  laboratorní diagnostika a sledování stavu paci-
entů] . 2005 . Available at: http://www .cskb .cz/res/file/do-
poruceni/DM_verze%202012 .pdf . Accessed June 20, 2015 . 
(in Czech)
14 . Reinauer H, Home P, Kanabasagapathy A, Heuck C-C . La-
boratory diagnosis and monitoring of diabetes mellitus . In: 
World Health Organization 2002 .
15 . Matthews JN, Altman DG, Campbell MJ, Royston P . Analysis of 
serial measurements in medical research . BMJ 1990;300:230-
35 . http://dx .doi .org/10 .1136/bmj .300 .6719 .230 .
16 . DeLong ER, DeLong DM, Clarke-Pearson DL . Comparing 
the areas under two or more correlated receiver operating 
characteristic curves: a nonparametric approach . Biome-
trics 1988;44:837-45 . http://dx .doi .org/10 .2307/2531595 .
17 . Youden WJ . Index for rating diagnostic tests . Can-
cer 1950;3:32-35 . http://dx .doi .org/10 .1002/1097-
0142(1950)3:1<32::AID-CNCR2820030106>3 .0 .CO;2-3 .
18 . Retnakaran R . Glucose tolerance status in pregnancy: a 
window to the future risk of diabetes and cardiovascular 
disease in young women . Curr Diabetes Rev 2009;5:239-44 . 
http://dx .doi .org/10 .2174/157339909789804378 .
19 . Kim C, Herman WH, Vijan S . Efficacy and cost of postpar-
tum screening strategies for diabetes among women with 
histories of gestational diabetes mellitus . Diabetes Care 
2007;30:1102-06 . http://dx .doi .org/10 .2337/dc06-2237 .
20 . Saaristo T, Moilanen L, Korpi-Hyövälti E, Vanhala M, Salte-
vo J, Niskanen L, et al . Lifestyle intervention for prevention 
of type 2 diabetes in primary health care: one-year follow-
up of the Finnish National Diabetes Prevention Program 
(FIN-D2D) . Diabetes Care 2010;33:2146-51 . http://dx .doi .
org/10 .2337/dc10-0410 .
21 . Wein P, Beischer NA, Sheedy MT . Studies of postnatal diabe-
tes mellitus in women who had gestational diabetes . Part 
2 . Prevalence and predictors of diabetes mellitus after de-
livery . Aust N Z J Obstet Gynaecol 1997;37:420-23 . http://
dx .doi .org/10 .1111/j .1479-828X .1997 .tb02450 .x .
22 . Schaefer-Graf UM, Buchanan TA, Xiang AH, Peters RK, 
Kjos SL . Clinical predictors for a high risk for the deve-
lopment of diabetes mellitus in the early puerperium in wo-
men with recent gestational diabetes mellitus . Am J Ob-
stet Gynecol 2002;186:751-56 . http://dx .doi .org/10 .1067/
mob .2002 .121895 .
23 . Akinci B, Celtik A, Genc S, Yener S, Demir T, Secil M, et al . 
Evaluation of postpartum carbohydrate intolerance and 
cardiovascular risk factors in women with gestational dia-
betes . Gynecol Endocrinol 2011;27:361-67 . http://dx .doi .or
g/10 .3109/09513590 .2010 .492885 .
24 . Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zin-
man B . Glucose intolerance in pregnancy and future risk of 
pre-diabetes or diabetes . Diabetes Care 2008;31:2026-31 . 
http://dx .doi .org/10 .2337/dc08-0972 .
25 . Ekelund M, Shaat N, Almgren P, Groop L, Berntorp K . Pre-
diction of postpartum diabetes in women with gestatio-
nal diabetes mellitus . Diabetologia 2010;53:452-57 . http://
dx .doi .org/10 .1007/s00125-009-1621-3 .
26 . Saisho Y, Miyakoshi K, Tanaka M, Matsumoto T, Minegis-
hi K, Yoshimura Y, et al . Antepartum oral disposition index 
as a predictor of glucose intolerance postpartum . Diabetes 
Care 2012;35:e32 . http://dx .doi .org/10 .2337/dc11-2549 .
27 . Rasmussen SS, Glümer C, Sandbaek A, Lauritzen T, Car-
stensen B, Borch-Johnsen K . Short-term reproducibility 
of impaired fasting glycaemia, impaired glucose toleran-
ce and diabetes The ADDITION study, DK . Diabetes Res 
Clin Pract 2008;80:146-52 . http://dx .doi .org/10 .1016/j .dia-
bres .2007 .11 .003 .
28 . Retnakaran R, Qi Y, Sermer M, Connelly PW, Zinman B, Han-
ley AJ . Comparison of National Diabetes Data Group and 
American Diabetes Association diagnostic criteria for ge-
stational diabetes in their identification of postpartum risk 
of glucose intolerance . Diabetes Res Clin Pract 2009;85:40-
46 . http://dx .doi .org/10 .1016/j .diabres .2009 .04 .008 .
29 . Retnakaran R, Qi Y, Sermer M, Connelly PW, Hanley AJ, Zin-
man B . The antepartum glucose values that predict neona-
tal macrosomia differ from those that predict postpartum 
prediabetes or diabetes: implications for the diagnostic 
criteria for gestational diabetes . J Clin Endocrinol Metab 
2009;94:840-45 . http://dx .doi .org/10 .1210/jc .2008-2434 .
30 . Carpenter MW, Coustan DR . Criteria for screening tests for 
gestational diabetes . Am J Obstet Gynecol 1982;144:768-
73 .
